(redirected from Urokinase-Type Plasminogen Activator)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Urokinase-Type Plasminogen Activator: Plasminogen activator inhibitor


tr.v. ac·ti·vat·ed, ac·ti·vat·ing, ac·ti·vates
1. To set in motion; make active or more active.
2. To organize or create (a military unit, for example): activate the National Guard.
3. To treat (sewage) with aeration and bacteria to aid decomposition.
4. Chemistry To accelerate a reaction in, as by heat.
5. Physics To make (a substance) radioactive.
6. Biology To convert (a molecule or cell) into a form that carries out a specific action: activate an enzyme; activate B cells.

ac′ti·va′tion n.
ac′ti·va′tor n.


(ˈæk təˌveɪ tər)

1. a person or thing that activates.
2. Chem., Biochem. a catalyst.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.activator - (biology) any agency bringing about activationactivator - (biology) any agency bringing about activation; a molecule that increases the activity of an enzyme or a protein that increases the production of a gene product in DNA transcription
substance - the real physical matter of which a person or thing consists; "DNA is the substance of our genes"
biological science, biology - the science that studies living organisms
activating agent - (mineral extraction) a surface-active chemical used in flotation process to increase the attraction to a specific mineral
catalyst, accelerator - (chemistry) a substance that initiates or accelerates a chemical reaction without itself being affected
sensitiser, sensitizer - (chemistry) a substance other than a catalyst that facilitates the start of a catalytic reaction
inhibitor - a substance that retards or stops an activity


[ˈæktɪˌveɪtəʳ] Nactivador m


n activador m
References in periodicals archive ?
Schmitt, "Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination," Journal of Clinical Oncology, vol.
Soluble urokinase-type plasminogen activator receptor (suPAR) has recently been suggested as a potential circulating factor in FSGS [9-13].
Elevated plasma soluble urokinase-type plasminogen activator receptor (suPAR) levels are associated with declines in estimated glomerular filtration rate and may predict progression to clinical chronic kidney disease, new research suggests.
6) Further, endotoxin-mediated urokinase-type plasminogen activator receptor expression, important in neutrophil recruitment, has been found to be mediated through tyrosine phosphorylation of phosphoglycerate kinase.
Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemla: a prospective cohort study.
Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Inhibition of urokinase-type plasminogen activator (uPA) abrogates myogenesis in vitro.
Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
The serine protease, urokinase-type plasminogen activator (uPA) plays an important role in tissue remodeling, cell migration and wound healing (Toriseva and Kahari, 2008; Watanabe et al.
ViroGates A/S (Birkerod, Denmark) has patented a method of diagnosing and/or prognosticating HIV infection in a subject comprising the steps of: (a) performing in vitro a measurement of the level of a marker in the form of (i) urokinase plasminogen activator receptor (uPAR), (ii) soluble urokinase plasminogen activator receptor (suPAR), (iii) urokinase-type plasminogen activator (uPA), (iv) one or more degradation products of (i), (ii) or (iii), and/or (v) an mRNA for (i), (ii) or (iii), in a biological fluid sample from a subject, and (b) using the measurement value obtained to evaluate the state of the subject.
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide and urokinase-type plasminogen activator in breast cancer patients.
Specifically, the researchers have examined the effects of alcohol and polyphenols on the expression of proteins and pathways that can lead to increased fibrinolysis (including, tissue-type plasminogen activator, t-PA; urokinase-type plasminogen activator, u-PA and plasminogen activator inhibitor type 1, PAI-1).